U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C17H20N4S
Molecular Weight 312.432
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OLANZAPINE

SMILES

CN1CCN(CC1)C2=NC3=CC=CC=C3NC4=C2C=C(C)S4

InChI

InChIKey=KVWDHTXUZHCGIO-UHFFFAOYSA-N
InChI=1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including http://www.priory.com/focus3.htm

Olanzapine is a novel antipsychotic agent marketed by Lilly & Co. It has a pleotrophic pharmacology and affects dopaminergic, serotonergic, muscarinic and adrenergic activities. Olanzapine is used to treat the symptoms of psychotic conditions such as schizophrenia and bipolar disorder (manic depression) in adults and children who are at least 13 years old. Olanzapine is sometimes used together with other antipsychotic medications or antidepressants. The mechanism of action of olanzapine, as with other drugs having efficacy in schizophrenia, is unknown. However, it has been proposed that this drug’s efficacy in schizophrenia is mediated through a combination of dopamine and serotonin type 2 (5HT2) antagonism. The mechanism of action of olanzapine in the treatment of acute manic or mixed episodes associated with bipolar I disorder is unknown. Olanzapine treatment led to rapid phosphorylation of kinases from all three pathways in PC12 cells. Phosphorylation of Akt was blocked with selective inhibitors (wortmannin and LY294002), which implicates phosphoinositide 3-kinase (PI3K) in the signaling cascade. Short-term mitogenic effects of olanzapine were abolished with a selective inhibitor of Akt, but not by inhibition of the ERK pathway. Olanzapine is metabolized by the cytochrome P450 system; principally by isozyme 1A2 and to a lesser extent by 2D6. By these mechanisms more than 40% of the oral dose, on average, is removed by the hepatic first-pass effect. Drugs or agents that increase the activity of CYP1A2, notably tobacco smoke, may significantly increase hepatic first-pass clearance of Olanzapine; conversely, drugs which inhibit 1A2 activity (examples: Ciprofloxacin, Fluvoxamine) may reduce Olanzapine clearance. The most common side effects appear to be somnolence and weight gain. About 11% of patients gain weight -especially if on a high starting dose and if they were underweight pre-treatment. Sexual dysfunction is a problem for many patients, although sexual dysfunction in schizophrneia does not appear to be primarily attributable to drugs.

CNS Activity

Originator

Approval Year

1996
225
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2778
Antagonist
2778
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
ZYPREXA

Approved Use

Olanzapine orally disintegrating tablets, USP are atypical antipsychotic indicated: As oral formulation for the: Treatment of schizophrenia. (1.1) Adults: Efficacy was established in three clinical trials in patients with schizophrenia: two 6-week trials and one maintenance trial. (14.1) Adolescents (ages 13 to 17): Efficacy was established in one 6-week trial in patients with schizophrenia (14.1). The increased potential (in adolescents compared with adults) for weight gain and dyslipidemia may lead clinicians to consider prescribing other drugs first in adolescents. (1.1) Acute treatment of manic or mixed episodes associated with bipolar I disorder and maintenance treatment of bipolar I disorder. (1.2) Adults: Efficacy was established in three clinical trials in patients with manic or mixed episodes of bipolar I disorder: two 3- to 4-week trials and one maintenance trial. (14.2) Adolescents (ages 13 to 17): Efficacy was established in one 3-week trial in patients with manic or mixed episodes associated with bipolar I disorder (14.2). The increased potential (in adolescents compared with adults) for weight gain and dyslipidemia may lead clinicians to consider prescribing other drugs first in adolescents. (1.2) Medication therapy for pediatric patients with schizophrenia or bipolar I disorder should be undertaken only after a thorough diagnostic evaluation and with careful consideration of the potential risks. (1.3) Adjunct to valproate or lithium in the treatment of manic or mixed episodes associated with bipolar I disorder. (1.2) Efficacy was established in two 6-week clinical trials in adults (14.2). Maintenance efficacy has not been systematically evaluated. As O lanzapine Orally Disintegrating Tablets, USP and Fluoxetine in Combination for the: Treatment of depressive episodes associated with bipolar I disorder. (1.5) Efficacy was established with Symbyax* (olanzapine and fluoxetine in combination); refer to the product label for Symbyax*. 1.1 Schizophrenia Olanzapine orally disintegrating tablets, USP are indicated for the treatment of schizophrenia. Efficacy was established in three clinical trials in adult patients with schizophrenia: two 6-week trials and one maintenance trial. In adolescent patients with schizophrenia (ages 13 to 17), efficacy was established in one 6-week trial [see Clinical Studies (14.1)

Launch Date

8.4404162E11
Primary
Approved
8429
ZYPREXA

Approved Use

Olanzapine orally disintegrating tablets, USP are atypical antipsychotic indicated: As oral formulation for the: Treatment of schizophrenia. (1.1) Adults: Efficacy was established in three clinical trials in patients with schizophrenia: two 6-week trials and one maintenance trial. (14.1) Adolescents (ages 13 to 17): Efficacy was established in one 6-week trial in patients with schizophrenia (14.1). The increased potential (in adolescents compared with adults) for weight gain and dyslipidemia may lead clinicians to consider prescribing other drugs first in adolescents. (1.1) Acute treatment of manic or mixed episodes associated with bipolar I disorder and maintenance treatment of bipolar I disorder. (1.2) Adults: Efficacy was established in three clinical trials in patients with manic or mixed episodes of bipolar I disorder: two 3- to 4-week trials and one maintenance trial. (14.2) Adolescents (ages 13 to 17): Efficacy was established in one 3-week trial in patients with manic or mixed episodes associated with bipolar I disorder (14.2). The increased potential (in adolescents compared with adults) for weight gain and dyslipidemia may lead clinicians to consider prescribing other drugs first in adolescents. (1.2) Medication therapy for pediatric patients with schizophrenia or bipolar I disorder should be undertaken only after a thorough diagnostic evaluation and with careful consideration of the potential risks. (1.3) Adjunct to valproate or lithium in the treatment of manic or mixed episodes associated with bipolar I disorder. (1.2) Efficacy was established in two 6-week clinical trials in adults (14.2). Maintenance efficacy has not been systematically evaluated. As O lanzapine Orally Disintegrating Tablets, USP and Fluoxetine in Combination for the: Treatment of depressive episodes associated with bipolar I disorder. (1.5) Efficacy was established with Symbyax* (olanzapine and fluoxetine in combination); refer to the product label for Symbyax*. 1.1 Schizophrenia Olanzapine orally disintegrating tablets, USP are indicated for the treatment of schizophrenia. Efficacy was established in three clinical trials in adult patients with schizophrenia: two 6-week trials and one maintenance trial. In adolescent patients with schizophrenia (ages 13 to 17), efficacy was established in one 6-week trial [see Clinical Studies (14.1)

Launch Date

8.4404162E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
17.3 ng/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/12895191
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OLANZAPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
712 ng × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/12895191
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OLANZAPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
28.7 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/12895191
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OLANZAPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33564555
unhealthy, 20 years
n = 1
Health Status: unhealthy
Condition: paranoid schizophrenia
Age Group: 20 years
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/33564555
Disc. AE: Rhabdomyolysis...
AEs leading to
discontinuation/dose reduction:
Rhabdomyolysis (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/33564555
5 mg 1 times / day steady, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/21086lbl.pdf
unhealthy, 83 years (range: 61-97 years)
n = 65
Health Status: unhealthy
Condition: psychiatric symptoms
Age Group: 83 years (range: 61-97 years)
Sex: M+F
Population Size: 65
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/21086lbl.pdf
Disc. AE: Accidental injury, Somnolence...
AEs leading to
discontinuation/dose reduction:
Accidental injury (1%)
Somnolence (3%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/21086lbl.pdf
300 mg 1 times / day multiple, oral
Highest studied dose
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s074,021086s048,021253s061lbl.pdf
unhealthy, adult
n = 67
Health Status: unhealthy
Age Group: adult
Population Size: 67
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s074,021086s048,021253s061lbl.pdf
Other AEs: Drowsiness, Slurred speech...
Other AEs:
Drowsiness
Slurred speech
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s074,021086s048,021253s061lbl.pdf
40 mg 1 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s074,021086s048,021253s061lbl.pdf
unhealthy, adult
n = 200
Health Status: unhealthy
Condition: schizophrenia |schizoaffective disorder
Age Group: adult
Sex: M+F
Population Size: 200
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s074,021086s048,021253s061lbl.pdf
Other AEs: Dizziness...
Other AEs:
Dizziness (6.6%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s074,021086s048,021253s061lbl.pdf
2 g single, oral
Overdose
Dose: 2 g
Route: oral
Route: single
Dose: 2 g
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s074,021086s048,021253s061lbl.pdf
unhealthy, adult
n = 1
Health Status: unhealthy
Age Group: adult
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s074,021086s048,021253s061lbl.pdf
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s074,021086s048,021253s061lbl.pdf
5 mg 1 times / day steady, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s074,021086s048,021253s061lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s074,021086s048,021253s061lbl.pdf
Disc. AE: Weight gain...
AEs leading to
discontinuation/dose reduction:
Weight gain (0.2%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s074,021086s048,021253s061lbl.pdf
5 mg 1 times / day steady, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s074,021086s048,021253s061lbl.pdf
unhealthy, old
Health Status: unhealthy
Condition: DEMENTIA-RELATED PSYCHOSIS
Age Group: old
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s074,021086s048,021253s061lbl.pdf
Other AEs: Adverse event...
Other AEs:
Adverse event (grade 5)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s074,021086s048,021253s061lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Rhabdomyolysis 1 patient
Disc. AE
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33564555
unhealthy, 20 years
n = 1
Health Status: unhealthy
Condition: paranoid schizophrenia
Age Group: 20 years
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/33564555
Accidental injury 1%
Disc. AE
5 mg 1 times / day steady, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/21086lbl.pdf
unhealthy, 83 years (range: 61-97 years)
n = 65
Health Status: unhealthy
Condition: psychiatric symptoms
Age Group: 83 years (range: 61-97 years)
Sex: M+F
Population Size: 65
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/21086lbl.pdf
Somnolence 3%
Disc. AE
5 mg 1 times / day steady, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/21086lbl.pdf
unhealthy, 83 years (range: 61-97 years)
n = 65
Health Status: unhealthy
Condition: psychiatric symptoms
Age Group: 83 years (range: 61-97 years)
Sex: M+F
Population Size: 65
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/21086lbl.pdf
Drowsiness
300 mg 1 times / day multiple, oral
Highest studied dose
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s074,021086s048,021253s061lbl.pdf
unhealthy, adult
n = 67
Health Status: unhealthy
Age Group: adult
Population Size: 67
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s074,021086s048,021253s061lbl.pdf
Slurred speech
300 mg 1 times / day multiple, oral
Highest studied dose
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s074,021086s048,021253s061lbl.pdf
unhealthy, adult
n = 67
Health Status: unhealthy
Age Group: adult
Population Size: 67
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s074,021086s048,021253s061lbl.pdf
Dizziness 6.6%
40 mg 1 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s074,021086s048,021253s061lbl.pdf
unhealthy, adult
n = 200
Health Status: unhealthy
Condition: schizophrenia |schizoaffective disorder
Age Group: adult
Sex: M+F
Population Size: 200
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s074,021086s048,021253s061lbl.pdf
Weight gain 0.2%
Disc. AE
5 mg 1 times / day steady, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s074,021086s048,021253s061lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s074,021086s048,021253s061lbl.pdf
Adverse event grade 5
5 mg 1 times / day steady, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s074,021086s048,021253s061lbl.pdf
unhealthy, old
Health Status: unhealthy
Condition: DEMENTIA-RELATED PSYCHOSIS
Age Group: old
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s074,021086s048,021253s061lbl.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
1587

substrate
1737
inhibitor
1767

substrate
1037
inhibitor
1852

substrate
1217
inhibitor
1612

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
1524

CYP2C19
1478

BSEP
402
CYP1A2
1054

FMO
35

P-gp
1537

BCRP
561

UGT2B10
127

UGT1A4
347

CYP2C19
991

CYP2E1
667
FATP2
5
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
1692
 moderate [Ki 36 uM]
CYP3A4
1925
 moderate [Ki 491 uM]
no (co-administration study)
Comment: olanzapine has no effect on diazepam or N-desmethyldiazepam
Page: 310.0
CYP2C9
1819
 moderate [Ki 715 uM]
no (co-administration study)
Comment: olanzapine has no effect on warfarin
Page: 310.0
CYP2D6
1891
 moderate [Ki 89 uM]
no (co-administration study)
Comment: olanzapine has no effect on imiprazine
Page: 310.0
CYP2C19
1553
 moderate [Ki 920 uM]
no (co-administration study)
Comment: olanzapine has no effect on diazepam or N-desmethyldiazepam
Page: 310.0
BSEP
403
 weak [IC50 54.57 uM]
OCTN2
71
 yes [IC50 1.06 uM]
FATP2
5
 yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP2C19
991
 no
CYP2C9
1037
 no
CYP2E1
667
 no
CYP2D6
1217
 weak
weak (co-administration study)
Comment: in vivo; imiprazine increases olanzapine exposure by 19%
Page: 308.0
BCRP
561
 yes [Ki >1000 uM]
CYP3A4
1737
 yes
FMO
35
 yes
P-gp
1537
 yes
UGT1A4
347
 yes
UGT2B10
127
 yes
CYP1A2
1054
 yes
yes (co-administration study)
Comment: carbamazepine increases olanzapine clearance by 50%; fluoxetine increased olanzapine Cmax and AUC; omeprazole and rifampin may increase olanzapine clearance
Page: 19, 20
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1647
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:7735
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:7735
ChemicalBook
CB04188690
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB04188690
ChemicalBook
CB34188691
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB34188691
ChemicalBook
CB52743465
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB52743465
ChemicalBook
CB64188692
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB64188692
ChemicalBook
CB6755515
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB6755515
MolPort
MolPort-002-885-845
https://www.molport.com/shop/molecule-link/MolPort-002-885-845
Selleck Chemicals
Olanzapine(Zyprexa)
http://www.selleckchem.com/products/Olanzapine(Zyprexa).html
ZINC
ZINC000052957434
http://zinc15.docking.org/substances/ZINC000052957434
eMolecules
902226
https://www.emolecules.com/cgi-bin/more?vid=902226
PubMed

PubMed

TitleDatePubMed
D2 receptor occupancy under recommended and high doses of olanzapine: an iodine-123-iodobenzamide SPECT study.
2000
Superior efficacy of olanzapine over haloperidol: analysis of patients with schizophrenia from a multicenter international trial.
2001
Weight change and atypical antipsychotic treatment in patients with schizophrenia.
2001
Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics.
2001
Introduction: a new era in the pharmacotherapy of psychotic disorders.
2001
Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone.
2001
An efficacy analysis of olanzapine treatment data in schizophrenia patients with catatonic signs and symptoms.
2001
The efficacy of a rapid-acting intramuscular formulation of olanzapine for positive symptoms.
2001
Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia.
2001
Rapid tranquilization with olanzapine in acute psychosis: a case series.
2001
Antipsychotic medications and the elderly: effects on cognition and implications for use.
2001
Olanzapine: an updated review of its use in the management of schizophrenia.
2001
Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia.
2001
Treatment of psychogenic polydipsia: comparison of risperidone and olanzapine, and the effects of an adjunctive angiotensin-II receptor blocking drug (irbesartan).
2001 Feb
Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.
2001 Feb
Priapism associated with polypharmacy.
2001 Feb
Tolerability and effectiveness of atypical antipsychotics in male geriatric inpatients.
2001 Feb
New onset diabetes and atypical antipsychotics.
2001 Feb
Supersensitivity psychosis in patients with schizophrenia after sudden olanzapine withdrawal.
2001 Feb
A case report of olanzapine-induced hypersensitivity syndrome.
2001 Feb
Olanzapine and hypertriglyceridemia.
2001 Feb
Screening for detection of new antidepressants, neuroleptics, hypnotics, and their metabolites in urine by GC-MS developed using rat liver microsomes.
2001 Feb
Fully automated on-line determination of olanzapine in serum for routine therapeutic drug monitoring.
2001 Feb
Effects of newer atypical antipsychotics on autonomic neurocardiac function: a comparison between amisulpride, olanzapine, sertindole, and clozapine.
2001 Feb
Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial.
2001 Feb
The economic consequences of a drug-drug interaction.
2001 Feb
Repeated episodes of hypothermia in a subject treated with haloperidol, levomepromazine, olanzapine, and thioridazine.
2001 Feb
Atypical antipsychotics and cardiovascular risk in schizophrenic patients.
2001 Feb
Traditional and new antipsychotic drugs differentially alter neurotransmission markers in basal ganglia-thalamocortical neural pathways.
2001 Feb
The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease.
2001 Jan
Short-term effects of olanzapine in Huntington disease.
2001 Jan
Bodyweight gain with atypical antipsychotics. A comparative review.
2001 Jan
Treatment of bipolar depression with twice-weekly fluoxetine: management of antidepressant-induced mania.
2001 Jan
Olanzapine-induced leukopenia with human leukocyte antigen profiling.
2001 Jan
Allelic variation in the 5-HT2C receptor (HT2RC) and the increase in slow wave sleep produced by olanzapine.
2001 Jan 1
Consistency of atypical antipsychotic superiority to placebo in recent clinical trials.
2001 Jan 1
Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine.
2001 Jan 1
Dopamine transporter density in young patients with schizophrenia assessed with [123]FP-CIT SPECT.
2001 Jan 15
[Olanzapine and pregnancy].
2001 Jan 21
Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum.
2001 Jan 26
A sensitive high-performance liquid chromatographic method using electrochemical detection for the analysis of olanzapine and desmethylolanzapine in plasma of schizophrenic patients using a new solid-phase extraction procedure.
2001 Jan 5
Olanzapine-lnduced hyperglycemic nonketonic coma.
2001 Mar
5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release.
2001 Mar
Atypical antipsychotics and hyperglycaemia.
2001 Mar
Dose-dependent olanzapine-associated leukopenia: three case reports.
2001 Mar
Low blood glucose and olanzapine.
2001 Mar
Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis.
2001 Mar
Electrooxidation potential as a tool in the early screening for new safer clozapine-like analogues.
2001 Mar 1
Quantitative determination of olanzapine in rat brain tissue by high-performance liquid chromatography with electrochemical detection.
2001 Mar 5
Separation of olanzapine, carbamazepine and their main metabolites by capillary electrophoresis with pseudo-stationary phases.
2001 Mar 5
Patents

Patents

07303764
5
07951798
5
20010039275
12
20020012680
32
JP2007509911A
7
JP2007512339A
43
JP2007525670A
148
JP2011508765A
9
JP2011524381A
7
JP2011528275A
455

Sample Use Guides

In Vivo Use Guide
Schizophrenia: Adults: Oral olanzapine should be administered on a once-a-day schedule without regard to meals, generally beginning with 5 to 10 mg initially, with a target dose of 10 mg/day within several days. Further dosage adjustments, if indicated, should generally occur at intervals of not less than 1 week, since steady state for olanzapine would not be achieved for approximately 1 week in the typical patient. Adolescents: Oral olanzapine should be administered on a once-a-day schedule without regard to meals with a recommended starting dose of 2.5 or 5 mg, with a target dose of 10 mg/day. Efficacy in adolescents with schizophrenia was demonstrated based on a flexible dose range of 2.5 to 20 mg/day in clinical trials, with a mean modal dose of 12.5 mg/day (mean dose of 11.1 mg/day). Bipolar I Disorder (Manic or Mixed Episodes): Adults: Oral olanzapine should be administered on a once-a-day schedule without regard to meals, generally beginning with 10 or 15 mg. Dosage adjustments, if indicated, should generally occur at intervals of not less than 24 hours, reflecting the procedures in the placebo-controlled trials. Adolescents: Oral olanzapine should be administered on a once-a-day schedule without regard to meals with a recommended starting dose of 2.5 or 5 mg, with a target dose of 10 mg/day. Efficacy in adolescents with bipolar I disorder (manic or mixed episodes) was demonstrated based on a flexible dose range of 2.5 to 20 mg/day in clinical trials, with a mean modal dose of 10.7 mg/day (mean dose of 8.9 mg/day). IntraMuscular: Agitation Associated with Schizophrenia and Bipolar I Mania: The efficacy of intramuscular olanzapine for injection in controlling agitation in these disorders was demonstrated in a dose range of 2.5 mg to 10 mg.
Route of Administration: Other
In Vitro Use Guide
Curator's Comment: Molecular mechanisms of the neuroprotection by olanzapine were explored, specifically the activation of various protein kinase signaling pathways including Akt/protein kinase B (PKB), extracellular-regulated kinase (ERK), ERK1/2, and mitogen-activated protein kinase (MAPK), p38. Olanzapine treatment led to rapid phosphorylation of kinases from all three pathways in PC12 cells. Phosphorylation of Akt was blocked with selective inhibitors (wortmannin and LY294002), which implicates phosphoinositide 3-kinase (PI3K) in the signaling cascade. Short-term mitogenic effects of olanzapine were abolished with a selective inhibitor of Akt, but not by inhibition of the ERK pathway.
Unknown
Name Type Language
OLANZAPINE
EMA EPAR   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
OLAZAX DISPERZI
Brand Name English
Olanzapine [WHO-DD]
Common Name English
OLAZAX
Brand Name English
OLANZAPINE [USP-RS]
Common Name English
OLANZAPINE [USP MONOGRAPH]
Common Name English
OLANZAPINE [VANDF]
Common Name English
SYMBYAX COMPONENT OLANZAPINE
Common Name English
LY-170053
Code English
OLANZAPINE CIPLA
Brand Name English
OLANZAPINE [USAN]
Common Name English
OLANZAPINE GLENMARK EUROPE
Brand Name English
OLANZAPINE [EP MONOGRAPH]
Common Name English
OLANZAPINE GLENMARK
Brand Name English
10H-THIENO(2,3-B)(1,5)BENZODIAZEPINE, 2-METHYL-4-(4-METHYL-1-PIPERAZINYL)-
Systematic Name English
OLANZAPINE [ORANGE BOOK]
Common Name English
2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine
Systematic Name English
OLANZAPINE [MI]
Common Name English
ZYPREXA VELOTAB
Brand Name English
OLANZAPINE COMPONENT OF LYBALVI
Brand Name English
OLANZAPINE TEVA
Brand Name English
ZALASTA
Brand Name English
LYBALVI COMPONENT OLANZAPINE
Brand Name English
OLANSEK
Brand Name English
OLANZAPINE [EMA EPAR]
Common Name English
OLANZAPINE [MART.]
Common Name English
OLANZAPINE MYLAN
Brand Name English
olanzapine [INN]
Common Name English
LY170053
Code English
OLANZAPINE COMPONENT OF SYMBYAX
Common Name English
OLANZAPINE [JAN]
Common Name English
ZYPREXA
Brand Name English
OLANZAPINE APOTEX
Brand Name English
Classification Tree Code System Code
WHO-VATC QN05AH03
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
EMA ASSESSMENT REPORTS OLAZAX (AUTHORIZED: SCHIZOPHRENIA)
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
EMA ASSESSMENT REPORTS OLANZAPINE TEVA (AUTHORIZED: BIPOLAR DISORDER)
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
EMA ASSESSMENT REPORTS OLAZAX DISPERZI (AUTHORIZED: SCHIZOPHRENIA)
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
WHO-ATC N05AH03
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
EMA ASSESSMENT REPORTS OLANZAPINE GLENMARK (AUTHORIZED: BIPOLAR DISORDER)
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
EMA ASSESSMENT REPORTS OLAZAX (AUTHORIZED: BIPOLAR DISORDER)
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
EMA ASSESSMENT REPORTS OLANZAPINE TEVA (AUTHORIZED: SCHIZOPHRENIA)
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
EMA ASSESSMENT REPORTS ZYPREXA VELOTAB (AUTHORIZED: BIPOLAR DISORDER)
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
NCI_THESAURUS C29710
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
EMA ASSESSMENT REPORTS ZALASTA (AUTHORIZED: BIPOLAR DISORDER)
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
EMA ASSESSMENT REPORTS OLANZAPINE MYLAN (AUTHORIZED: SCHIZOPHRENIA)
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
EMA ASSESSMENT REPORTS OLANZAPINE GLENMARK EUROPE (AUTHORIZED: BIPOLAR DISORDER)
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
EMA ASSESSMENT REPORTS OLANZAPINE GLENMARK EUROPE (AUTHORIZED: SCHIZOPHRENIA)
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
LIVERTOX NBK548842
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
NDF-RT N0000175430
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
EMA ASSESSMENT REPORTS ZYPREXA (AUTHORIZED: SCHIZOPHRENIA)
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
EMA ASSESSMENT REPORTS OLAZAX DISPERZI (AUTHORIZED: BIPOLAR DISORDER)
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
EMA ASSESSMENT REPORTS OLANZAPINE CIPLA (WITHDRAWN: SCHIZOPHRENIA)
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
EMA ASSESSMENT REPORTS OLANZAPINE CIPLA (WITHDRAWN: BIPOLAR DISORDER)
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
EMA ASSESSMENT REPORTS OLANZAPINE GLENMARK (AUTHORIZED: SCHIZOPHRENIA)
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
EMA ASSESSMENT REPORTS ZYPREXA (AUTHORIZED: BIPOLAR DISORDER)
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
EMA ASSESSMENT REPORTS ZYPREXA VELOTAB (AUTHORIZED: SCHIZOPHRENIA)
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
EMA ASSESSMENT REPORTS OLANZAPINE MYLAN (AUTHORIZED: BIPOLAR DISORDER)
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
EMA ASSESSMENT REPORTS ZALASTA (AUTHORIZED: SCHIOZPHRENIA)
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
EMA ASSESSMENT REPORTS OLANSEK (WITHDRAWN: BIPOLAR DISORDER)
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
EMA ASSESSMENT REPORTS OLANZAPINE APOTEX (AUTHORIZED: BIPOLAR DISORDER)
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
EMA ASSESSMENT REPORTS OLANZAPINE APOTEX (AUTHORIZED: SCHIZOPHRENIA)
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
EMA ASSESSMENT REPORTS OLANSEK (WITHDRAWN: SCHIZOPHRENIA)
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
Code System Code Type Description
MERCK INDEX
m8184
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
PRIMARY Merck Index
PUBCHEM
135398745
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
PRIMARY
INN
6956
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
PRIMARY
EPA CompTox
DTXSID9023388
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
PRIMARY
IUPHAR
47
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
PRIMARY
SMS_ID
100000085471
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
PRIMARY
NCI_THESAURUS
C47639
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
PRIMARY
DAILYMED
N7U69T4SZR
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
PRIMARY
DRUG CENTRAL
1982
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
PRIMARY
CAS
132539-06-1
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
PRIMARY
HSDB
8155
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
PRIMARY
USAN
DD-64
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
PRIMARY
CHEBI
7735
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
PRIMARY
RXCUI
61381
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
PRIMARY RxNorm
RS_ITEM_NUM
1478301
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
PRIMARY
EVMPD
SUB09426MIG
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
PRIMARY
WIKIPEDIA
OLANZAPINE
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
PRIMARY
DRUG BANK
DB00334
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
PRIMARY
ChEMBL
CHEMBL715
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
PRIMARY
LACTMED
Olanzapine
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
PRIMARY
FDA UNII
N7U69T4SZR
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
PRIMARY
ACTIVE MOIETY
Structure of OLANZAPINE
METABOLITE (PARENT)
Structure of N-DESMETHYLOLANZAPINE
METABOLITE (PARENT)
Structure of LY-290411
SALT/SOLVATE (PARENT)
Structure of OLANZAPINE HYDROCHLORIDE
SALT/SOLVATE (PARENT)
Structure of OLANZAPINE TARTRATE
SALT/SOLVATE (PARENT)
Structure of OLANZAPINE PAMOATE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966